Oncology and advanced solid tumors
Clinical research is centered on advanced solid tumors, with interest in treatment settings where disease control and tumor response remain limited.
- Anti-tumor activity
- Safety and tolerability
- Therapeutic response assessment
The sponsor’s activity in this area reflects a focus on cancer therapeutics and the evaluation of targeted approaches for difficult-to-treat solid malignancies.
Immune checkpoint and angiogenesis pathways
Research interest includes therapies directed at PD-1 and VEGFR2, linking immune modulation with tumor vascular biology.
- PD-1 pathway targeting
- VEGFR2-related vascular inhibition
- Dual-target antibody approaches
This therapeutic domain places emphasis on mechanisms relevant to immuno-oncology and anti-angiogenic treatment strategies.
Early clinical development in oncology
The sponsor funds early-stage clinical research aimed at defining dose selection, clinical safety, and initial evidence of antitumor efficacy.
- Recommended Phase 2 dose identification
- Clinical tolerability
- Preliminary efficacy signals
Its research profile is concentrated on translating novel biologic therapies into patient populations with limited treatment options.
